Healthpeak Properties

DOC · NYSE

$18.76+$0.36 (+1.96%)TodayMarket closed · Oct 20, 7:45 PM ET

Prev close $18.40

DOC analyst rating

HoldConsensus of 19 analysts over the last 12 months. 21% rate it a buy.

Strong buy0
Buy4
Hold15
Underperform0
Sell0

12-month price target · 20 analysts

Average $23.37 (+24.6% upside)

Low: $17.17
Now: $18.76
High: $30.45

Upgrades and downgrades

The latest rating actions, newest first

DOC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
Wells Fargo	Oct 19, 2026	Maintains	Equal-Weight	$22.00 → $19.00	48%
UBS	Oct 13, 2026	Maintains	Neutral	$21.50 → $20.00	—
Barclays	Oct 13, 2026	Maintains	Equal-Weight	$24.00 → $21.00	38%
Evercore ISI Group	Sep 21, 2026	Maintains	In-Line	$23.00 → $22.00	27%
Jefferies	Sep 15, 2026	Initiates	Hold	$22.00 → $21.00	33%
Barclays	Aug 31, 2026	Maintains	Equal-Weight	$23.00 → $24.00	38%
Baird	Aug 13, 2026	Maintains	Outperform	$21.00 → $24.00	35%
Citigroup	Aug 11, 2026	Maintains	Neutral	$20.00 → $22.00	44%
RBC Capital	Aug 10, 2026	Maintains	Outperform	$21.00 → $24.00	58%
Cantor Fitzgerald	Aug 6, 2026	Maintains	Neutral	$20.00 → $23.00	55%

The case for and against

Updated Jan 19, 2026

Bull case

Healthpeak Properties benefits from a robust and diversified healthcare portfolio, consisting of approximately 700 properties primarily in medical office and life science assets. The company is poised for growth, especially with new development projects totaling $148 million, which are largely pre-leased at approximately 80% and are expected to yield mid-7% upon stabilization. This strategic expansion underscores Healthpeak's potential for solid revenue growth and enhances its overall attractiveness as a stable investment in the healthcare sector.

Bear case

Healthpeak Properties is facing a rating downgrade due to an increase in Lab tenant credit risk and weak Q2 leasing performance, leading to a revised forecast of a compound annual growth rate (CAGR) for FFOPS/AFFOPS of +1%/-1% for 2026-2027, down from +2%/+1%. The adjustment in the applied P/AFFOPS multiple to 12.0x reflects these concerns, alongside the anticipated challenges in Lab occupancy attributed to slow capital raising projected for the latter half of 2025. Overall, these factors contribute to a negative financial outlook for Healthpeak Properties, indicating potential downside risks to its earnings in the coming years.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.